Global markets

Life Biosciences Series B $80 million

Boston biotech locks in Series B for ER-100 epigenetic reprogramming ophthalmology candidates.

Primary sources · 1
Fierce Biotech fundraising
← View the full 2026-04-10 (Friday) issue
What you're reading now arrives in your inbox daily at 21:00 UTC.

Get today's brief every day at 21:00 UTC

7 must-reads · 17 fields · tracked storylines delivered to your inbox daily. Pick only the fields you want; unsubscribe anytime.

Past issues →